Advertisement

Digestive Diseases and Sciences

, Volume 56, Issue 5, pp 1460–1471 | Cite as

Pharmacological Basis for the Medicinal Use of Psyllium Husk (Ispaghula) in Constipation and Diarrhea

  • Malik Hassan Mehmood
  • Nauman Aziz
  • Muhammad Nabeel Ghayur
  • Anwarul-Hassan Gilani
Original Article

Abstract

Background

The objective of this study was to determine the pharmacological basis of the medicinal use of psyllium husk (Ispaghula) in gastrointestinal motility disorders.

Methods

In-vivo studies were conducted on mice, and isolated rabbit jejunum and guinea-pig ileum were used in in-vitro experiments.

Results

The crude extract of Ispaghula (Po.Cr) had a laxative effect in mice at 100 and 300 mg/kg, which was partially sensitive to atropine or SB203186 (5-HT4 antagonist). At higher doses (500 and 1,000 mg/kg), Po.Cr had antisecretory and antidiarrheal activity. In guinea-pig ileum, Po.Cr (1–10 mg/ml) had a stimulatory effect, which was partially sensitive to atropine or SB203186. In rabbit jejunum, Po.Cr had a partially atropine-sensitive stimulatory effect followed by relaxation at 10 mg/ml. The relaxation was inhibited by the presence of l-NAME, a nitric oxide (NO) synthase inhibitor, or methylene blue, a guanylyl cyclase inhibitor. Similarly, the relaxant effect of Po.Cr on K+ (80 mM)-induced contractions, was attenuated in the presence of l-NAME or methylene blue. Activity-directed fractionation of Po.Cr revealed that the gut stimulatory and inhibitory constituents were widely distributed in the aqueous and organic fractions.

Conclusion

This study demonstrates that Ispaghula has a gut-stimulatory effect, mediated partially by muscarinic and 5-HT4 receptor activation, which may complement the laxative effect of its fiber content, and a gut-inhibitory activity possibly mediated by blockade of Ca2+ channels and activation of NO-cyclic guanosine monophosphate pathways. This may explain its medicinal use in diarrhea. It is, perhaps, also intended by nature to offset an excessive stimulant effect.

Keywords

Plantago ovata Psyllium husk Ispaghula Spasmodic Laxative Antispasmodic Antidiarrheal 

Notes

Acknowledgments

This study was funded by the Pakistan Medical Research Council. We thank Dr Graeme Cane, Head, Center of English Language, for language correction.

Conflict of interest

No competing financial interests exist.

References

  1. 1.
    Ouyang H, Chen JD. Review article: therapeutic roles of acupuncture in functional gastrointestinal disorders. Aliment Pharmacol Ther. 2004;20:831–841.PubMedCrossRefGoogle Scholar
  2. 2.
    Cheng CW, Bian ZX, Wu TX. Systematic review of Chinese herbal medicine for functional constipation. World J Gastroenterol. 2009;15:4886–4895.PubMedCrossRefGoogle Scholar
  3. 3.
    Ramkumar D, Rao SS. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol. 2005;100:936–971.PubMedCrossRefGoogle Scholar
  4. 4.
    Tack J, Müller-Lissner S. Treatment of chronic constipation: current pharmacologic approaches and future directions. Clin Gastroenterol Hepatol. 2009;7:502–508.PubMedCrossRefGoogle Scholar
  5. 5.
    Nemes Z. Diarrhea from the infectologist’s point of view. Orv Hetil. 2009;150:353–361.PubMedCrossRefGoogle Scholar
  6. 6.
    Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ. 2003;81:197–204.PubMedGoogle Scholar
  7. 7.
    Liebelt EL. Clinical and laboratory evaluation and management of children with vomiting and dehydration. Curr Opin Pediatr. 1998;10:461–469.PubMedCrossRefGoogle Scholar
  8. 8.
    WHO. Diarrhea: Why Children Are Still Dying and What Can Be Done?. Geneva: World Health Organization; 2009.Google Scholar
  9. 9.
    Gilani AH, Rahman A. Trends in ethnopharmacology. J Ethnopharmacol. 2005;100:43–49.PubMedCrossRefGoogle Scholar
  10. 10.
    Gilani AH. Constipation and its treatment with natural drugs used in Pakistan. In: Capasso F, Mascolo N, eds. Natural Drugs and the Digestive Tract. Rome: EMSI; 1992:117–121.Google Scholar
  11. 11.
    Pasricha PJ. Treatment of disorders of bowel motility and water flux. In: Brunton LL, Lazo JS, Parker KL, eds. The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw–Hill; 2006:983–1008.Google Scholar
  12. 12.
    Duke JA, Bogenschutz-Godwin MJ, Du Celliar J, Duke PAK. Plantago ovata F. In: Hand Book of Medicinal Herbs. 2nd ed. Boca Raton: CRC Press; 2002:591–592.Google Scholar
  13. 13.
    Duke JA. Plantago ovata F. In: Handbook of Phytochemical Constituents of GRAS Herbs and Other Economic Plants. 2nd ed. Boca Raton: CRC Press; 1992:472–473.Google Scholar
  14. 14.
    Deters AM, Schroder KR, Smiatek T, Hensel A. Ispaghula (Plantago ovata) seed husk polysaccharides promote proliferation of human epithelial cells (skin keratinocytes and fibroblasts) via enhanced growth factor receptors and energy production. Planta Med. 2005;71:33–39.PubMedCrossRefGoogle Scholar
  15. 15.
    Van Craeyveld V, Delcour JA, Courtin CM. Ball milling improves extractability and affects molecular properties of psyllium (Plantago ovata Forsk.) seed husk arabinoxylan. J Agric Food Chem. 2008;56:11306–11311.PubMedCrossRefGoogle Scholar
  16. 16.
    Elli M, Cattivelli D, Soldi S, Bonatti M, Morelli L. Evaluation of prebiotic potential of refined psyllium (Plantago ovata) fiber in healthy women. J Clin Gastroenterol. 2008;42:S174–S176.PubMedCrossRefGoogle Scholar
  17. 17.
    Zaman V, Manzoor SM, Zaki M, Aziz N, Gilani AH. The presence of antiamoebic constituent(s) in psyllium husk. Phytother Res. 2002;16:78–79.PubMedCrossRefGoogle Scholar
  18. 18.
    Pirotta M. Irritable bowel syndrome—the role of complementary medicines in treatment. Aust Fam Physician. 2009;38:966–968.PubMedGoogle Scholar
  19. 19.
    Rodriguez-Cabezas ME, Galvez J, Camuesco D, et al. Intestinal anti-inflammatory activity of dietary fiber (Plantago ovata seeds) in HLA-B27 transgenic rats. Clin Nutr. 2003;22:463–471.PubMedCrossRefGoogle Scholar
  20. 20.
    Odes HS, Madar Z. A double-blind trial of a celandin, aloevera and psyllium laxative preparation in adult patients with constipation. Digestion. 1991;49:65–71.PubMedCrossRefGoogle Scholar
  21. 21.
    Cheskin LJ, Kamal N, Crowell MD, Schuster MM, Whitehead WE. Mechanisms of constipation in older persons and effects of fiber compared with placebo. J Am Geriatr Soc. 1995;43:666–669.PubMedGoogle Scholar
  22. 22.
    McRorie JW, Daggy BP, Morel JG, Diersing PS, Miner PB, Robinson M. Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther. 1998;12:491–497.PubMedCrossRefGoogle Scholar
  23. 23.
    Johanson JF. Review of the treatment options for chronic constipation. Med Gen Med. 2007;9:25.Google Scholar
  24. 24.
    Bolla G, Sartore G. The psyllium fibre for the treatment of functional constipation in children. Pediatr Med Chir. 2008;30:146–148.PubMedGoogle Scholar
  25. 25.
    Gilani AH, Nauman A, Khan A, Khan S, Zaman V. Laxative effect of Ispaghula: physical or chemical effects? Phytother Res. 1998;12:63–65.CrossRefGoogle Scholar
  26. 26.
    Smalley JR, Klish WJ, Campbell MA, Brown MR. Use of psyllium in the management of chronic nonspecific diarrhea of childhood. J Pediatr Gastroenterol Nutr. 1982;1:361–363.PubMedCrossRefGoogle Scholar
  27. 27.
    Qvitzau S, Matzen P, Madsen P. Treatment of chronic diarrhea: loperamide versus ispaghula husk and calcium. Scand J Gastroenterol. 1988;23:1237–1240.PubMedCrossRefGoogle Scholar
  28. 28.
    Washington N, Harris M, Mussellwhite A, Spiller RC. Moderation of lactulose-induced diarrhea by psyllium: effects on motility and fermentation. Am J Clin Nutr. 1998;67:317–321.PubMedGoogle Scholar
  29. 29.
    Murphy J, Stacey D, Crook J, Thompson B, Panetta D. Testing control of radiation-induced diarrhea with a psyllium bulking agent: a pilot study. Can Oncol Nurs J. 2000;10:96–100.PubMedGoogle Scholar
  30. 30.
    Fouda AM, Berika MY. Evaluation of the effect of hydroalcoholic extract of Zingiber officinale rhizomes in rat collagen-induced arthritis. Basic Clin Pharmacol Toxicol. 2009;104:262–271.PubMedCrossRefGoogle Scholar
  31. 31.
    Williamson EM, Okpako DT, Evans FJ. Pharmacological Methods in Phytotherapy Research. Chichester: Wiley; 1998:15–23.Google Scholar
  32. 32.
    Evans WC. Phytochemistry. In: Trease and Evans Pharmacognosy. 5th ed. Delhi, India: Elsevier; 2006:135–150.Google Scholar
  33. 33.
    National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996:1–7.Google Scholar
  34. 34.
    Kadowaki M, Nagakura Y, Tomoi M, Mori J, Kohsaka M. Effect of FK1052, a potent 5-hydroxytryptamine-3 and 5-hydroxytryptamine-4 receptor dual antagonist, on colonic function in vivo. J Pharmacol Exp Ther. 1993;266:274–280.Google Scholar
  35. 35.
    Gilani AH, Ghayur MN, Khalid A, Zaheer-ul-Haq MA, Choudhary MI, Rahman A. Presence of antispasmodic, antidiarrheal, antisecretory, calcium antagonist and acetylcholinesterase inhibitory steroidal alkaloids in Sarcococca saligna. Planta Med. 2005;71:120–125.CrossRefGoogle Scholar
  36. 36.
    Borrelli F, Capasso F, Capasso R, et al. Effect of Boswellia serrata on intestinal motility in rodents: inhibition of diarrhea without constipation. Br J Pharmacol. 2006;148:553–560.PubMedCrossRefGoogle Scholar
  37. 37.
    Godfraind T, Miller R, Wibo M. Calcium antagonism and calcium entry blockade. Pharmacol Rev. 1986;38:312–326.Google Scholar
  38. 38.
    Gilani AH, Khan A, Ghayur MN, Herzig JW. Antispasmodic effects of Rooibos tea (Aspalathus linearis) are mediated predominantly through potassium channel activation. Basic Clin Pharmacol Toxicol. 2006;99:365–373.PubMedCrossRefGoogle Scholar
  39. 39.
    Gilani AH, Khan AU, Raoof M, et al. Gastrointestinal, selective airways and urinary bladder relaxant effects of Hyoscyamus niger are mediated through dual blockade of muscarinic receptors and Ca++ channels. Fund Clin Pharmacol. 2008;22:87–99.CrossRefGoogle Scholar
  40. 40.
    Adeyemi OO, Okpo SO, Young-Nwafor CC. The relaxant activity of the methanolic extract of Acanthus montanus on intestinal smooth muscles. J Ethnopharmacol. 1999;68:169–173.PubMedCrossRefGoogle Scholar
  41. 41.
    Ghayur MN, Gilani AH. Pharmacological basis for the medicinal use of ginger in gastrointestinal disorders. Dig Dis Sci. 2005;50:1889–1897.PubMedCrossRefGoogle Scholar
  42. 42.
    Brown JH, Taylor P. Muscarinic receptor agonists and antagonists. In: Brunton LL, Lazo JS, Parker KL, eds. The Pharmacological Basis of Therapeutics. 11th ed. ed. New York: McGraw–Hill; 2006:183–200.Google Scholar
  43. 43.
    Sander-Bush E, Mayer SE. 5-Hydroxytryptamine (serotonin): agonist and antagonists. In: Brunton LL, Lazo JS, Parker KL, eds. The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw–Hill; 2006:297–315.Google Scholar
  44. 44.
    Gilani AH, Shaheen F, Christopoulos A, Mitchelson F. Interaction of ebeinone, an alkaloid from Fritillaria imperialis, at two muscarinic acetylcholine receptor subtypes. Life Sci. 1997;60:535–544.PubMedCrossRefGoogle Scholar
  45. 45.
    Gilani AH, Ghayur MN, Khan A. Ca++ antagonist and cholinergic activities explain the medicinal use of olive in gut disorders. Nutr Res. 2006;26:277–283.CrossRefGoogle Scholar
  46. 46.
    Ghayur MN, Gilani AH, Houghton PJ. Species differences in the gut-stimulatory effects of radish seeds. J Pharm Pharmacol. 2005;57:1493–1501.PubMedGoogle Scholar
  47. 47.
    McLean PG, Coupar IM. 5-HT4 receptor antagonist affinities of SB207710, SB205008, and SB203186 in the human colon, rat oesophagus, and guinea-pig ileum peristaltic reflex. Naunyn Schmiedebergs Arch Pharmacol. 1995;352:132–140.PubMedCrossRefGoogle Scholar
  48. 48.
    Grider JR, Foxx-Orenstein AE, Jin JG. 5-HT4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea-pig intestine. Gastroenterology. 1998;115:370–380.PubMedCrossRefGoogle Scholar
  49. 49.
    Baker DE. Tegaserod for the treatment of constipation-predominant irritable bowel syndrome. Rev Gastroenterol Disord. 2001;1:187–198.PubMedGoogle Scholar
  50. 50.
    Gale JD. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. Adv Ther. 2009;5:519–530.CrossRefGoogle Scholar
  51. 51.
    Al-Judaibi B, Chande N, Gregor J. Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation. Can J Clin Pharmacol. 2010;17:194–200.Google Scholar
  52. 52.
    Reynolds IJ, Gould RJ, Snyder SH. Loperamide: blockade of calcium channels as a mechanism for antidiarrhea l effects. J Pharmacol Exp Ther. 1984;231:628–632.PubMedGoogle Scholar
  53. 53.
    Lee CW, Sarna SK, Singaram C, Casper MA. Ca++ channel blockade by verapamil inhibits GMCs and diarrhea during small intestinal inflammation. Am J Physiol. 1997;273:785–794.Google Scholar
  54. 54.
    Billman GE. The antiarrythmic effects of the calcium antagonists. In: Epstein M, ed. Calcium Antagonists in Clinical Medicine. Philadelphia: Hanley and Belfus; 1992:183–212.Google Scholar
  55. 55.
    Iwao I, Terada Y. On the mechanism of diarrhea due to castor oil. Jpn J Pharmacol. 1962;12:137–145.PubMedCrossRefGoogle Scholar
  56. 56.
    Kumar A, Kumar N, Vij JC, Sarin SK, Anand BS. Optimum dosage of ispaghula husk in patients with irritable bowel syndrome: correlation of symptom relief with whole gut transit time and stool weight. Gut. 1987;28:150–155.PubMedCrossRefGoogle Scholar
  57. 57.
    Ganong WF. Review of Medical Physiology. California: Appleton and Lange; 1991:263.Google Scholar
  58. 58.
    Sharif NA, Xu SX, Yanni JM. Histamine receptor-subtype affinities, selectivities, and potencies of emedastine, a novel H1-selective antagonist, and other ocularly employed antihistamines. Drug Dev Res. 1994;33:448–453.CrossRefGoogle Scholar
  59. 59.
    Wien R, Mason DF, Edge ND, Langston GT. The ganglion blocking properties of homologous compounds in the methonium series. Br J Pharmacol. 1952;7:534–541.Google Scholar
  60. 60.
    Buchheit KH, Engel G, Mutschler E, Richardson B. Study of the contractile effect of 5-hydroxytryptamine (5-HT) in the isolated longitudinal muscle strip from guinea-pig ileum. Naunyn Schmiedebergs Arch Pharmacol. 1985;329:36–41.PubMedCrossRefGoogle Scholar
  61. 61.
    Meulemans AL, Schuurkes JA. Is the action of cisapride on the guinea-pig ileum mediated via 5-HT4 receptors? Eur J Pharmacol. 1992;212:51–59.PubMedCrossRefGoogle Scholar
  62. 62.
    Mascolo N, Izzo AA, Barbato F, Capasso F. Inhibitors of nitric oxide synthetase prevent castor-oil-induced diarrhea in the rat. Br J Clin Pharmacol. 1993;108:861–864.Google Scholar
  63. 63.
    Patil CS, Singh VP, Jain NK, Kulkarni SK. Inhibitory effect of sildenafil on gastrointestinal smooth muscle: role of NO-cGMP transduction pathway. Indian J Exp Biol. 2005;43:167–171.PubMedGoogle Scholar
  64. 64.
    Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol. 1995;48:184–188.PubMedGoogle Scholar
  65. 65.
    Brading AF. How do drugs initiate contractions in smooth muscles? Trends Pharmacol Sci. 1981;2:261–265.CrossRefGoogle Scholar
  66. 66.
    Fleckenstein A. Specific pharmacology of Ca++ in myocardium cardiac pacemakers and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1993;17:149–166.CrossRefGoogle Scholar
  67. 67.
    Ghayur MN, Gilani AH. Species differences in the prokinetic effects of ginger. Int J Food Sci Nutr. 2006;57:65–73.PubMedCrossRefGoogle Scholar
  68. 68.
    McLeod RL, Gertner SB, Hey JA. Species differences in the cardiovascular responses to histamine H3 receptor activation. Eur J Pharmacol. 1994;259:211–214.PubMedCrossRefGoogle Scholar
  69. 69.
    Akah PA, Oli AN, Enwerem NM, Gamaneil K. Preliminary studies on purgative effect of Carica papaya root extract. Fitoterapia. 1997;68:327–331.Google Scholar
  70. 70.
    Ramstad E. Pharmacognosy. London, New York: Blakiston Division, New York: McGraw–Hill; 1959:28–50.Google Scholar
  71. 71.
    Di-Carlo G, Autore G, Izzo A, et al. Inhibition of intestinal motility and secretion by flavonoids in mice and rats: structure activity relationships. J Pharma Pharmacol. 1993;45:1054–1059.CrossRefGoogle Scholar
  72. 72.
    Carlo GD, Mascolo N, Izzo AA, Capasso F. Flavonoids: Old and new class of natural therapeutic drug. Life Sci. 1999;65:337–339.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Malik Hassan Mehmood
    • 1
    • 2
  • Nauman Aziz
    • 1
  • Muhammad Nabeel Ghayur
    • 1
    • 3
  • Anwarul-Hassan Gilani
    • 1
  1. 1.Natural Product Research Division, Department of Biological and Biomedical SciencesAga Khan University Medical CollegeKarachiPakistan
  2. 2.Department of Pharmacology, Faculty of PharmacyUniversity of KarachiKarachiPakistan
  3. 3.Department of MedicineMcMaster University, St. Joseph’s HospitalHamiltonCanada

Personalised recommendations